Fractyl Health (NASDAQ:GUTS) Price Target Lowered to $8.00 at HC Wainwright

Key Points

• HC Wainwright has lowered its price target for Fractyl Health (NASDAQ:GUTS) from $9.00 to $8.00 while maintaining a "buy" rating.
• Fractyl Health's stock has seen a significant increase of 29.2%, reaching a price of $1.31.
• The company's EPS report for the last quarter showed a loss of ($0.53), which was worse than the consensus estimate of ($0.37).

Fractyl Health (NASDAQ:GUTS - Get Free Report) had its price target lowered by research analysts at HC Wainwright from $9.00 to $8.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock.

GUTS has been the subject of several other research reports. LADENBURG THALM/SH SH started coverage on shares of Fractyl Health in a research note on Thursday, August 28th. They issued a "buy" rating and a $3.60 price objective for the company. Canaccord Genuity Group dropped their target price on shares of Fractyl Health from $12.00 to $6.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. Four analysts have rated the stock with a Buy rating, According to MarketBeat.com, Fractyl Health presently has a consensus rating of "Buy" and an average price target of $6.90.

Fractyl Health Stock Up 29.2%

GUTS stock traded up $0.30 during midday trading on Friday, hitting $1.31. The company's stock had a trading volume of 71,169,109 shares, compared to its average volume of 917,717. The company has a debt-to-equity ratio of 4.61, a current ratio of 1.22 and a quick ratio of 1.22. Fractyl Health has a twelve month low of $0.83 and a twelve month high of $3.48. The company's fifty day moving average price is $1.21 and its 200 day moving average price is $1.43. The stock has a market capitalization of $65.63 million, a P/E ratio of -0.62 and a beta of 1.55.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.16). Fractyl Health had a negative return on equity of 584.35% and a negative net margin of 73,864.52%. As a group, equities research analysts predict that Fractyl Health will post -1.61 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of GUTS. Jane Street Group LLC raised its holdings in Fractyl Health by 125.8% during the fourth quarter. Jane Street Group LLC now owns 22,700 shares of the company's stock worth $47,000 after buying an additional 12,648 shares during the last quarter. HighTower Advisors LLC raised its holdings in Fractyl Health by 57.9% during the first quarter. HighTower Advisors LLC now owns 40,921 shares of the company's stock worth $49,000 after buying an additional 15,000 shares during the last quarter. Catalyst Funds Management Pty Ltd acquired a new position in Fractyl Health during the second quarter worth $26,000. Bank of New York Mellon Corp raised its holdings in Fractyl Health by 54.5% during the first quarter. Bank of New York Mellon Corp now owns 64,020 shares of the company's stock worth $76,000 after buying an additional 22,572 shares during the last quarter. Finally, Nuveen Asset Management LLC raised its holdings in Fractyl Health by 61.5% during the fourth quarter. Nuveen Asset Management LLC now owns 72,958 shares of the company's stock worth $150,000 after buying an additional 27,778 shares during the last quarter.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.